Skip to main content
Teaser
Kapseln
Teaser
Teaser

Vaccines

Chitosan non-particulate vaccine delivery systems

Chitosan non-particulate vaccine delivery systems

chitosan adjuvanz 31 märz 2025 bild


The development of safe and effective vaccines is a major challenge. In addition to generating an adequate immune response, vaccines must also remain stable over time – both inside and outside the body. In their review article, Masimov and Wasan present various applications of chitosan and chitosan derivatives as adjuvants in the development of particulate and non-particulate vaccines.


Masimov R, Wasan EK. Chitosan non-particulate vaccine delivery systems. J Pharm Pharm Sci. 2024 Jul 24;27:12921. doi: 10.3389/jpps.2024.12921. PMID: 39114808; PMCID: PMC11303186.

Influence of different chitosan derivatives on the immunogenicity of PLGA nanoparticles

Vaccines based on recombinant protein antigens often require immunostimulants. Both nanoparticles and chitosan and its derivatives can enhance immunogenicity. For this reason, in the presented studies, PLGA nanoparticles were functionalized with different chitosan derivatives and optimized as effect enhancers for the pneumococcal protein antigen PspA4Pro.

SARS-CoV-2 research with chitosan - publications to date

The corona virus disease COVID-19 has changed the world. To combat the pandemic, researchers and companies around the world are working to develop vaccines and medicines. Chitosan also has potential in the area of vaccine development and functionalization of protective equipment such as respirators. We have prepared summaries of recent publications on chitosan as an aid in the fight against corona.

Chitosan for vaccine development against SARS-CoV-2

The global spread of SARS-CoV-2 can only be contained through vaccine development. Vector vaccines (DNA and viral) can be produced rapidly and inexpensively with current synthesis technologies. Challenges with DNA vaccines include degradation by DNases, inefficient uptake by antigen-presenting cells, and low immunogenicity. The Quil-A-loaded chitosan particulate adjuvant system (QAC) enables transport of plasmid DNA directly to target cells and delayed release over time. Here, we present two recent studies about chitosan-based delivery systems for vaccines.

Chitosan as adjuvant for vaccines

Adjuvants in vaccines are potent enhancers, which ensure that even small amounts of pathogens induce a permanent immune response. They are particularly necessary for inactivated vaccines and vaccines with antigen subunits. Several studies investigated chitosan as an adjuvant or antigen delivery system in various formulations (gels, aqueous dispersion, micro- and nanoparticles).

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.